scholarly journals Treatment of endometrial cancer at the Joliot Curie Institute in Dakar: about 30 cases

2021 ◽  
Vol 1 (1) ◽  
pp. 28-30
Author(s):  
Jaafar Thiam ◽  
E Kahatwa ◽  
Sidy Ka ◽  
Mamadou Moustapha Dieng ◽  
Doudou Diouf ◽  
...  
Keyword(s):  
Radiation Therapy ◽  
Endometrial Cancer ◽  
Stage Iv ◽  
Pelvic Lymphadenectomy ◽  
Common Type ◽  
Endometrioid Adenocarcinoma ◽  
External Radiotherapy ◽  
Radiation Cystitis ◽  
Effective Treatment Modality

AIM: To study the therapeutic aspects of endometrial cancer at the Joliot Curie Institute in Dakar. MATERIALS AND METHODS: This is a retrospective study conducted at the Joliot Curie Institute in Dakar including all cases of endometrial cancer confirmed by histology between January 2012 and December 2016. RESULTS: There were 30 cases of endometrial cancer over a period of five years. Endometrioid adenocarcinoma was the most common type of histology and was found in 25 patients, or 84% of cases. The patients were classified as stages I and II of FIGO in 43% of cases, stage III in 24% of cases and stage IV in 33% of cases. Colpo-hysterectomy with pelvic lymphadenectomy (CHL) was the main surgical procedure performed. External radiotherapy was performed in three patients or 10%. A case of radiation cystitis and radiodermatitis were recorded as a radiotherapy complication. No patient received brachytherapy. Chemotherapy was performed in 17 patients, ie 56.6%. She was adjuvant in 10 patients, or 34% of cases. Pelvic recurrences were noted in three patients who underwent 10% surgery. After 13 months of follow-up, survival was 50%. CONCLUSION: The most effective treatment modality for endometrial cancer at the Joliot Curie Institute was surgery followed by chemotherapy and Radiation therapy.

scholarly journals Endometrial cancer with implantation metastasis to vagina: a case report

2020 ◽  
Vol 9 (3) ◽  
pp. 1303
Author(s):  
Muhammad Eimaduddin Sapiee ◽  
Wan Rosmidah Wan Abas ◽  
Roziana Ramli ◽  
Muhd Afif Mohd Yusof ◽  
Ahmad Fazlin Nasaruddin
Keyword(s):  
Endometrial Cancer ◽  
Lymphovascular Invasion ◽  
Pelvic Lymphadenectomy ◽  
Endometrioid Adenocarcinoma ◽  
Rare Occurrence ◽  
Urethral Orifice ◽  
Implantation Metastasis ◽  
Lost To Follow Up ◽  
Vaginal Introitus

Authors present a case of vaginal implantation metastasis following a diagnosis of endometrial cancer. A 58-year-old lady presented with postmenopausal bleeding and was later diagnosed to have endometrial cancer. She underwent an extra-fascial hysterectomy and bilateral salpingo-oophrorectomy with pelvic lymphadenectomy for Stage 3A endometrioid adenocarcinoma of the endometrium. The lymph nodes and cervix were free from the disease and no lymphovascular invasion was seen on the pathological specimen. She defaulted adjuvant radiotherapy and was lost to follow up. Six months later she had a tumour recurrence at the vaginal introitus just below the urethral orifice and awal from the vaginal vault with similar histopathological findings as previous cancer. This case highlights the rare occurrence of implantation metastasis of endometrial cancer.

Is CTLA4 targeting the Achilles’ heel of Merkel cell carcinoma?

2021 ◽  
Vol 39 (15_suppl) ◽  
pp. e21567-e21567
Author(s):  
Richard Cheng Han Wu ◽  
Kari Lynn Kendra ◽  
Dukagjin Blakaj ◽  
Hiral A. Shah ◽  
Joanne M. Jeter ◽  
...  
Keyword(s):  
Radiation Therapy ◽  
Cell Carcinoma ◽  
Merkel Cell Carcinoma ◽  
Neuroendocrine Differentiation ◽  
Stage Iv ◽  
Lymph Node Involvement ◽  
Primary Objective ◽  
Merkel Cell ◽  
Number Of Patients

e21567 Background: Merkel Cell Carcinoma (MCC) is a cutaneous malignancy with neuroendocrine differentiation, linked to infection with polyomavirus (MCPyV) in 80% of cases. PD1 inhibitors have recently been approved for this indication with ORR, 33-56%; CR, 11-24%; PFS, about 17 months; OS, about 12 months. Nivolumab was tested in the neoadjuvant setting with similar responses with pathological CR, 47%. Methods: Adjuvant pilot study (NCT03798639) with two immunotherapy regimens administered for one year to patients with completely resected MCC at high risk of recurrence (primary lesion of 2 cm or greater, positive or close margins ( < 2 cm), perineural or lymphovascular invasion, mitotic index ≥ 20 mitotic figures per mm2, lymph node involvement (stage pIIIA or pIIIB) with or without extracapsular extension, or completely resected stage IV disease). Arm 1, nivolumab 480 mg q 4 wks and radiation therapy (RT) 50-60 Gy in 25-30 fractions, per standard of care. Arm 2, nivolumab 240 mg q 2 wks and ipilimumab 1 mg/kg q 6 wks. Primary objective was feasibility and completion of treatment in this population. Safety profile (CTCAE v5.0) and recurrence-free survival (RFS) after 18 months were secondary endpoints. Patients were randomly allocated 1:1. Results: Ten patients were screened from January 2019 until April 2020, when COVID put the study on hold and the sponsor discontinued the free drug supply. Seven were enrolled. Four were allocated to Arm 1 and three to Arm 2. Patient characteristics in Table. All patients have completed treatment and are in follow-up. Arm 1: all four patients completed radiation therapy and immunotherapy with no dose modifications or delays. Arm 2: one patient had nivolumab delayed 2 weeks for cellulitis, and another missed the last four last doses of nivolumab for cholecystitis and pancreatitis requiring surgery, unrelated to the immunotherapy. Adverse events (AE) were as expected. Arm1 caused more grade 2 and 3 AEs then Arm2 (no grade 3). One patient each discontinued treatment, in Arm 1 for progression and Arm 2 for immunotoxicity (temporal arteritis grade 2). One recurrence was observed in Arm 1 and none in Arm 2. Conclusions: The number of patients expected to recur at 1 year is 20%. Our observed data is insufficient to establish efficacy. However with no patient recurring in the ipilimumab arm after 18 months of follow-up and lower observed side effects, we would favor this regimen for the next trial. Clinical trial information: NCT03798639. [Table: see text]

scholarly journals Endometrial Cancer with Sarcoidosis in Regional Lymph Nodes: A Case Report

2015 ◽  
Vol 8 (3) ◽  
pp. 409-415 ◽  
Author(s):  
Satoshi Tamauchi ◽  
Yuji Shimomura ◽  
Hiromi Hayakawa
Keyword(s):  
Endometrial Cancer ◽  
Lymph Node ◽  
Lymph Nodes ◽  
Pelvic Lymphadenectomy ◽  
Preoperative Imaging ◽  
Endometrioid Adenocarcinoma ◽  
Regional Lymph Nodes ◽  
Lymph Node Swelling ◽  
Histological Confirmation ◽  
Noncaseating Granulomas

Sarcoidosis is a chronic, multisystemic disease commonly affecting the lungs and lymphatic system and is characterized by the formation of noncaseating granulomas. Although several reports are available on cases developing both sarcoidosis and cancer metachronously, cases of simultaneous diagnosis of these diseases have rarely been reported. A 67-year-old woman diagnosed with endometrial cancer had developed systemic lymph node swelling, including bilateral hilar, paraaortic, and a few pelvic lymph nodes, as observed on preoperative imaging. During surgery, frozen sections of a paraaortic lymph node were examined, revealing noncaseating granulomas compatible with sarcoidosis. Next, modified radical hysterectomy, bilateral salpingo-oophorectomy, and pelvic lymphadenectomy were performed. Postoperative pathological analysis revealed endometrioid adenocarcinoma of the uterus, and no metastasis but noncaseating granulomas were detected in the resected lymph nodes. Postoperatively, we identified cutaneous sarcoidosis and uveitis in the presence of a tuberculin-negative test. On the basis of these findings, we diagnosed the patients with endometrial cancer complicated by sarcoidosis. She underwent adjuvant chemotherapy, and at the 1-year follow-up, the lymph node swelling due to sarcoidosis was stable, and no recurrence of the cancer was observed. This turned out to be a case of early endometrial cancer mimicking advanced cancer by sarcoidosis. Histological confirmation and additional examination for sarcoidosis are necessary in cancer patients suspected of sarcoidosis.

Stereotactic body radiation therapy as palliative management for incurable thoracic malignancies.

2021 ◽  
Vol 39 (15_suppl) ◽  
pp. e24097-e24097
Author(s):  
Grace S. Ahn ◽  
Andrew Bruggeman ◽  
Edmund M. Qiao ◽  
James Don Murphy ◽  
Ajay Sandhu
Keyword(s):  
Radiation Therapy ◽  
Local Control ◽  
Background Radiation ◽  
Stage Iv ◽  
Ct Imaging ◽  
Incurable Cancer ◽  
Symptom Palliation ◽  
Thoracic Malignancies

e24097 Background: Radiation therapy plays an important role in symptom palliation for patients with incurable cancer. Currently limited data exists regarding the role of SBRT vs conformal radiation for the palliation of symptoms due to malignancy. We report the symptom management and local control of palliative SBRT for incurable thoracic malignancies at a single institution. Methods: We retrospectively identified patients who underwent palliative SBRT between Jan 1st, 2009 and March 26th, 2019. Patients all had thoracic tumors that were not candidates for curative radiation due to age, stage, comorbidity, and/or prior treatment. We identified courses with total doses between 25-50 Gy (median 40) and total fractions between 3-10 (median 5). Symptoms such as cough, chest pain, hemoptysis, and shortness of breath were assessed at time of consult and first follow-up between 1-6 months post treatment. We also reviewed follow-up CT imaging to evaluate for local control using RECIST criteria. Descriptive statistics were used to evaluate patients’ clinicopathologic data and symptom palliation. Local control was analyzed via Kaplan-Meier method. Results: Of the 76 patients who completed palliative SBRT to 92 total lung lesions, 45 patients reported symptoms at consult and completed 50 courses of radiation to 55 lesions. Within this symptomatic cohort, average age was 71 (range, 42-93), 32 were female (58%), and most were stage IV (n = 42, 76%). Most lesions treated were non-small cell lung cancer (n = 34, 62%) while the most common primary site of metastatic lesions was colorectal (n = 6, 11%). Additional primary sites included breast, renal, sarcoma, and others (n = 15, 27%). Of the 53 lesions treated with follow-up within 6 months, 21 (40%) showed relief of at least 1 symptom and 31 (58%) showed stable symptoms. Only 1 patient (2%) showed symptom progression. All patients with hemoptysis at presentation achieved hemostasis following SBRT. Among 48 treated lesions with follow-up CT imaging, 1 (2%) showed complete response, 28 (58%) showed partial response (PR), 15 (31%) showed stable disease (SD), and 4 (8%) showed progressive disease. With further follow-up (median 23 months), 30 of the 53 lesions with initial PR or SD demonstrated local control until death. Conclusions: There is conflicting literature regarding the ideal palliative radiation dose for thoracic tumors. SBRT has the advantage of allowing a higher biologic dose without protracted treatment courses in the setting of palliation of symptoms. Our symptomatic cohort showed good symptom palliation and long-term local control of treated lesions. Prospective studies are required to further confirm the role of palliative SBRT for symptomatic thoracic tumors.

scholarly journals Breast cancer during pregnancy

2019 ◽  
Vol 1 (1) ◽  
pp. 52-54
Author(s):  
Sandhya C. Acharya ◽  
Aarati Shah
Keyword(s):  
Breast Cancer ◽  
Radiation Therapy ◽  
Pregnant Women ◽  
Cancer Registry ◽  
Hormonal Treatment ◽  
Common Type ◽  
Advanced Stage ◽  
Cancer Society ◽  
Total Cancer

Breast cancer during pregnancy is rare accounting for 1 in around 3000 pregnant women as per the American cancer society. According to hospital-based cancer registry of Nepal, breast cancer accounts for 9.2% of total cancer cases and pregnancy associated breast cancer accounts for 0.15% of the total breast cancer. Though rare, breast cancer is the most common type of cancer found during pregnancy and that too in advanced stage because of the hormonal interplay during pregnancy. Here we present a case of breast cancer during pregnancy which was treated successfully with chemotherapy, surgery, radiation therapy and is on hormonal treatment. Patient is on regular follow up for the last six years without evidence of recurrence of the disease, and the baby has achieved normal developmental milestones though exposed to chemotherapy in utero.

External Beam, Brachytherapy, or Chemotherapy? Defining Adjuvant Therapy for Early-Stage and High- and High–Intermediate-Risk Endometrial Cancer

2019 ◽  
Vol 37 (21) ◽  
pp. 1778-1784 ◽  
Author(s):  
Joanne Wei-un Jang ◽  
Larissa Janeen Lee
Keyword(s):  
Endometrial Cancer ◽  
Early Stage ◽  
Relevant Literature ◽  
Myometrial Invasion ◽  
Laparoscopic Hysterectomy ◽  
Figo Stage ◽  
Pelvic Lymphadenectomy ◽  
Endometrioid Adenocarcinoma ◽  
Pelvic Magnetic Resonance Imaging ◽  
Gynecology And Obstetrics

The Oncology Grand Rounds series is designed to place original reports published in the Journal into clinical context. A case presentation is followed by a description of diagnostic and management challenges, a review of the relevant literature, and a summary of the authors’ suggested management approaches. The goal of this series is to help readers better understand how to apply the results of key studies, including those published in Journal of Clinical Oncology, to patients seen in their own clinical practice. A 54-year-old postmenopausal female with a history of stroke and carotid endarterectomy presented with 3 weeks of vaginal bleeding with passage of clots. Gynecologic exam revealed a 3-cm barrel-shaped cervix with friability at the os and no appreciable parametrial involvement. Cervical biopsy showed high-grade endometrioid adenocarcinoma. Pelvic magnetic resonance imaging demonstrated a 9.9-cm × 4.5-cm × 6.2-cm mass extending from the uterus to the cervix with greater than 50% myometrial invasion (MMI; Fig 1 ). Total laparoscopic hysterectomy, bilateral salpingo-oophorectomy, and pelvic lymphadenectomy revealed International Federation of Gynecology and Obstetrics (FIGO) stage II endometrial cancer: a 12-cm grade 3 endometrioid adenocarcinoma with 80% MMI and lymphovascular invasion (LVI) involving the outer half of the cervical stroma ( Fig 1 ), and without pelvic lymph node involvement.

scholarly journals Endometrial Adenocarcinoma in a 27-Year-Old Woman

2010 ◽  
Vol 3 ◽  
pp. CCRep.S5346 ◽  
Author(s):  
Anis Fadhlaoui ◽  
Jamel Ben Hassouna ◽  
Mohamed Khrouf ◽  
Fethi Zhioua ◽  
Anis Chaker
Keyword(s):  
Risk Factors ◽  
Radiation Therapy ◽  
Endometrial Cancer ◽  
Young Women ◽  
Endometrial Adenocarcinoma ◽  
Young Patients ◽  
Pelvic Lymphadenectomy ◽  
Therapeutic Options ◽  
Younger Patients ◽  
Lh Rh

Background Endometrial adenocarcinoma usually occurs after menopause, but in 2%–14% of cases, it occurs in young patients (less than 40 years of age) who are eager to preserve their fertility. Its treatment includes hysterectomy, bilateral salpingo-oophorectomy and pelvic lymphadenectomy, and, in some cases, radiation therapy. Aim To describe a case of endometrial adenocarcinoma occurring in a young woman and to undertake a literature review of risk factors and therapeutic options proposed for young women wishing to preserve their fertility. Case We report a case of endometrial cancer in a 27-year-old woman treated for resistant menorrhagia and cared for in our department as well as in the Salah Azaiez Institute. Conclusion Endometrial adenocarcinoma rarely occurs in young women. In such cases, other therapeutic options can be proposed: progesterone therapy and LH-RH (Luteinzing-Hormone-Releasing-Hormone) agonists therapy in order to preserve fertility in younger patients.

scholarly journals Successful anti-PD-1 therapy in metastatic endometrial cancer with microsatellite instability: a case report

2019 ◽  
Vol 15 (1) ◽  
pp. 73-77
Author(s):  
T. T. Andabekov ◽  
M. K. Rodina ◽  
G. A. Raskin ◽  
K. G. Cham ◽  
I. O. Rutkin
Keyword(s):  
Endometrial Cancer ◽  
Partial Response ◽  
Mismatch Repair ◽  
Malignant Tumors ◽  
Short Review ◽  
Endometrioid Adenocarcinoma ◽  
Mismatch Repair Deficiency ◽  
Repair Deficiency ◽  
Anticancer Treatment

High efficacy of anti-PD-1 therapy has been shown in malignant tumors with mismatch repair deficiency. According to the literature review, mismatch repair deficiency is determined in 20–40 % of all endometrial cancer cases and up to 48 % of its endometrioid subtype. We report the short review of the recent literature and the case of durable partial response on pembrolizumab immunotherapy in a patient with a metastatic endometrioid adenocarcinoma with MMR-deficiency progressed on 2 chemotherapy lines. Partial response was achieved after 6th course, treatment was stopped after 8th course. Patient is on follow-up without any anticancer treatment for 11 months. Partial response lasts for 13 months, with further reduction in tumor size. The treatment was well tolerated without adverse events.

Adjuvant Pelvic Radiation Therapy in Endometrial Cancer: The Pro Argument

2010 ◽  
Vol 20 (Suppl 2) ◽  
pp. S67-S69
Author(s):  
Ida Ackerman
Keyword(s):  
Radiation Therapy ◽  
Endometrial Cancer ◽  
Disease Free Survival ◽  
External Beam Radiation ◽  
Endometrioid Adenocarcinoma ◽  
External Beam ◽  
Beam Radiation ◽  
Free Survival ◽  
Pelvic Radiation ◽  
Disease Free

Adjuvant external beam pelvic radiation therapy for stage I endometrial cancer has become increasingly confusing and controversial. Despite repeated studies showing a disease-free survival benefit to the therapy, its role is being questioned because overall survival has not been demonstrated.By using evidence from the literature, including the most recent randomized data, an argument is made for the use of external beam pelvic radiotherapy for a 63-year-old woman who has undergone a total abdominal hysterectomy and bilateral salpingo-oophorectomy for a grade 2 endometrioid adenocarcinoma of the uterus with 9 of 12 mm of invasion and the presence of lymphovascular space involvement. Her risk of relapse is approximately 25%, and adjuvant external beam radiation can improve her disease-free survival and even possibly improve her chances of cure.

Sign in / Sign up

Export Citation Format

Share Document